Clinical trials: Metastatic Non-Small-Cell Lung Cancer
Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's…
- Conditions
- Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
- Trial name
- MDX1106-03 (NCT00730639)
- Testing
- BMS-936558 (MDX-1106)
- Where
- 13 sites in United States
- Volunteers
- 395 people
- Sponsor
- Bristol-Myers Squibb
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.
- Trial name
- NCT05513664
- Testing
- Osimertinib
- Where
- 24 sites in China
- Volunteers
- 80 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure.
- Trial name
- NCT01903993
- Testing
- Docetaxel, Atezolizumab
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Lung Cancer
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic…
- Trial name
- NCT07232849
- Testing
- HRS-4508 tablet
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non Small Cell Lung Cancer
A Study in Non Small Cell Lung Cancer
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer.
- Trial name
- NCT01139775
- Testing
- Pemetrexed, Cisplatin, LY2603618
- Where
- 24 sites in Germany, Spain
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA®) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT03875092
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with…
- Trial name
- NCT03409614
- Testing
- REGN2810, REGN2810/chemo/ipi, Chemotherapy
- Where
- 133 sites in United States, Austria and 16 more
- Volunteers
- 789 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined with Carboplatin and Pemetrexed/ Paclitaxel as…
- Trial name
- NCT04647344
- Testing
- AK104 plus Carboplatin and Pemetrexed, AK104 plus Carboplatin and paclitaxel
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Akeso
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Non-Small Cell Lung Cancer
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
- Trial name
- CheckMate 9LA (NCT03215706)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 116 sites in United States, Argentina and 17 more
- Volunteers
- 719 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Advanced Solid Tumors
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors.
- Conditions
- Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
- Trial name
- NCT03893955
- Testing
- ABBV-927, ABBV-368, ABBV-181
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination…
- Trial name
- PolyDamas (NCT05908734)
- Testing
- Cetrelimab, Amivantamab
- Where
- 44 sites in United States, Brazil and 7 more
- Volunteers
- 71 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.